186 related articles for article (PubMed ID: 11443849)
41. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
42. Diagnosis and treatment of medullary thyroid cancer.
Modigliani E; Franc B; Niccoli-sire P
Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Dec; 14(4):631-49. PubMed ID: 11289739
[TBL] [Abstract][Full Text] [Related]
43. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
Eng C; Mulligan LM
Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
[TBL] [Abstract][Full Text] [Related]
44. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A.
Schulte KM; Machens A; Fugazzola L; McGregor A; Diaz-Cano S; Izatt L; Aylwin S; Talat N; Beck-Peccoz P; Dralle H
J Clin Endocrinol Metab; 2010 Sep; 95(9):E92-7. PubMed ID: 20554711
[TBL] [Abstract][Full Text] [Related]
45. Multiple endocrine neoplasia type iia: report of a family with a study of three generations in qatar.
Zirie M; Mohammed I; El-Emadi M; Haider A
Endocr Pract; 2001; 7(1):19-27. PubMed ID: 11250764
[TBL] [Abstract][Full Text] [Related]
46. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.
Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T
Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265
[TBL] [Abstract][Full Text] [Related]
47. Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred.
Castro MR; Thomas BC; Richards ML; Zhang J; Morris JC
Thyroid; 2013 Dec; 23(12):1547-52. PubMed ID: 23461807
[TBL] [Abstract][Full Text] [Related]
48. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
Ponder BA
Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
[No Abstract] [Full Text] [Related]
49. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
50. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
51. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
[TBL] [Abstract][Full Text] [Related]
52. Multiple endocrine neoplasia type 2B.
Nakata S; Okugi H; Saitoh Y; Takahashi H; Shimizu K
Int J Urol; 2001 Jul; 8(7):398-400. PubMed ID: 11442663
[TBL] [Abstract][Full Text] [Related]
53. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
54. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
55. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
[TBL] [Abstract][Full Text] [Related]
56. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
[TBL] [Abstract][Full Text] [Related]
57. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine.
Schuffenecker I; Ginet N; Goldgar D; Eng C; Chambe B; Boneu A; Houdent C; Pallo D; Schlumberger M; Thivolet C; Lenoir GM
Am J Hum Genet; 1997 Jan; 60(1):233-7. PubMed ID: 8981969
[No Abstract] [Full Text] [Related]
58. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2.
Mulligan LM; Ponder BA
J Clin Endocrinol Metab; 1995 Jul; 80(7):1989-95. PubMed ID: 7608246
[No Abstract] [Full Text] [Related]
59. Multiple endocrine neoplasia type 2: an overview.
Moline J; Eng C
Genet Med; 2011 Sep; 13(9):755-64. PubMed ID: 21552134
[TBL] [Abstract][Full Text] [Related]
60. Multiple endocrine neoplasia type 2.
Forster-Gibson CJ; Mulligan LM
Eur J Cancer; 1994; 30A(13):1969-74. PubMed ID: 7734209
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
